BACKGROUND: AdGV.EGR.TNF.11D (TNFerade™ Biologic) is a replication-deficient adenoviral vector expressing human tumor necrosis factor alpha (TNF-α) under the control of the chemoradiation-inducible EGR-1 promoter. TNF-α has been shown to function as a radiation sensitizer. We conducted a phase I dose escalation study to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of TNFerade™ Biologic, when added to chemoradiotherapy in poor prognosis patients with recurrent, previously irradiated head and neck cancer (HNC). METHODS: TNFerade™ Biologic was injected intratumorally on day 1 of each 14-day cycle and dose-escalated in log increments from 4 × 10(9) to 4 × 10(11) PU. Daily radiation, infusional 5-fluorouracil (5-FU), and hydroxyurea were given on days 1-5 for seven cycles (FHX). Tumor biopsies were obtained before, during, and after treatment. RESULTS: Fourteen patients were treated. DLT was reached at a dose level of 3 (4 × 10(11) PU) with three thrombotic events. The response rate was 83.3%. The median survival was 9.6 months. One patient (7.1%) remained alive 3 years after treatment. Biopsies were obtained in 90% of patients. Nearly all tumors expressed adenovirus receptors, TNF-α, and TNF-α receptors. Adenoviral DNA was detected in three biopsies from one patient. CONCLUSIONS: TNFerade™ Biologic can be safely integrated with FHX chemoradiotherapy at an MTD of 4 × 10(10) PU. Monitoring for thrombotic events is indicated.
BACKGROUND: AdGV.EGR.TNF.11D (TNFerade™ Biologic) is a replication-deficient adenoviral vector expressing humantumor necrosis factor alpha (TNF-α) under the control of the chemoradiation-inducible EGR-1 promoter. TNF-α has been shown to function as a radiation sensitizer. We conducted a phase I dose escalation study to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of TNFerade™ Biologic, when added to chemoradiotherapy in poor prognosis patients with recurrent, previously irradiated head and neck cancer (HNC). METHODS:TNFerade™ Biologic was injected intratumorally on day 1 of each 14-day cycle and dose-escalated in log increments from 4 × 10(9) to 4 × 10(11) PU. Daily radiation, infusional 5-fluorouracil (5-FU), and hydroxyurea were given on days 1-5 for seven cycles (FHX). Tumor biopsies were obtained before, during, and after treatment. RESULTS: Fourteen patients were treated. DLT was reached at a dose level of 3 (4 × 10(11) PU) with three thrombotic events. The response rate was 83.3%. The median survival was 9.6 months. One patient (7.1%) remained alive 3 years after treatment. Biopsies were obtained in 90% of patients. Nearly all tumors expressed adenovirus receptors, TNF-α, and TNF-α receptors. Adenoviral DNA was detected in three biopsies from one patient. CONCLUSIONS:TNFerade™ Biologic can be safely integrated with FHX chemoradiotherapy at an MTD of 4 × 10(10) PU. Monitoring for thrombotic events is indicated.
Authors: R De Crevoisier; C Domenge; P Wibault; S Koscielny; A Lusinchi; F Janot; S Bobin; B Luboinski; F Eschwege; J Bourhis Journal: Cancer Date: 2001-06-01 Impact factor: 6.860
Authors: Thomas Calzascia; Marc Pellegrini; Håkan Hall; Laurent Sabbagh; Nobuyuki Ono; Alisha R Elford; Tak W Mak; Pamela S Ohashi Journal: J Clin Invest Date: 2007-12 Impact factor: 14.808
Authors: Corey J Langer; Jonathan Harris; Eric M Horwitz; Nicos Nicolaou; Merrill Kies; Walter Curran; Stuart Wong; Kian Ang Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: H J Mauceri; M A Beckett; H Liang; H G Sutton; S Pitroda; E Galka; E Efimova; T Darga; N N Khodarev; C R King; M C Posner; S Hellman; D W Kufe; R R Weichselbaum Journal: Cancer Gene Ther Date: 2008-10-31 Impact factor: 5.987
Authors: R De Crevoisier; J Bourhis; C Domenge; P Wibault; S Koscielny; A Lusinchi; G Mamelle; F Janot; M Julieron; A M Leridant; P Marandas; J P Armand; G Schwaab; B Luboinski; F Eschwege Journal: J Clin Oncol Date: 1998-11 Impact factor: 44.544
Authors: H Bobby Gaspar; Samantha Cooray; Kimberly C Gilmour; Kathryn L Parsley; Stuart Adams; Steven J Howe; Abdulaziz Al Ghonaium; Jinhua Bayford; Lucinda Brown; E Graham Davies; Christine Kinnon; Adrian J Thrasher Journal: Sci Transl Med Date: 2011-08-24 Impact factor: 17.956
Authors: Ralph E Vatner; Benjamin T Cooper; Claire Vanpouille-Box; Sandra Demaria; Silvia C Formenti Journal: Front Oncol Date: 2014-11-28 Impact factor: 6.244
Authors: Sean M O'Cathail; Tzveta D Pokrovska; Timothy S Maughan; Kerry D Fisher; Leonard W Seymour; Maria A Hawkins Journal: Front Oncol Date: 2017-07-24 Impact factor: 6.244
Authors: Séan M O'Cathail; Steven Davis; Jane Holmes; Richard Brown; Kerry Fisher; Leonard Seymour; Richard Adams; James Good; David Sebag-Montefiore; Tim Maughan; Maria A Hawkins Journal: Radiat Oncol Date: 2020-06-12 Impact factor: 3.481